• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Laura C Coates, Oliver FitzGerald, +7 authors Philip S Helliwell
  • Medicine
  • The Journal of Rheumatology
  • 2014 (First Publication: 1 April 2014)
  • This module reflected work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to develop and validate composite disease activity measures in psoriaticExpand
  • Rieke Alten, Christof Pohl, +9 authors Clifton O Bingham
  • Medicine
  • The Journal of Rheumatology
  • 2011 (First Publication: 1 August 2011)
  • Rheumatoid arthritis (RA) patients and healthcare professionals (HCP) recognize that episodic worsening disease activity, often described as a “flare,” is a common feature of RA that can contributeExpand
  • Lesley Ann Saketkoo, Shikha Mittoo, +5 authors Eric L Matteson
  • Medicine
  • The Journal of Rheumatology
  • 2014 (First Publication: 1 April 2014)
  • Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality. Great efforts are under wayExpand
  • Roy M Fleischmann, Vibeke Strand, Bethanie Wilkinson, Kenneth K Kwok, Eustratios Bananis
  • Medicine
  • RMD Open
  • 2016 (First Publication: 1 April 2016)
  • Objective To compare the relationship between clinical measures and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with tofacitinib or methotrexate (MTX). MethodsExpand
  • Edward C. Keystone, Robert Bm Landewé, +6 authors Desirée van der Heijde
  • Medicine
  • 2013 (First Publication: 1 June 2013)
  • Background In the RAPID 1 randomized clinical trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements in signs and symptomsExpand